Breast Cancer Research and Treatment

, Volume 124, Issue 2, pp 433–439

Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer

  • Song Yao
  • William E. Barlow
  • Kathy S. Albain
  • Ji-Yeob Choi
  • Hua Zhao
  • Robert B. Livingston
  • Warren Davis
  • James M. Rae
  • I-Tien Yeh
  • Laura F. Hutchins
  • Peter M. Ravdin
  • Silvana Martino
  • Alan P. Lyss
  • C. Kent Osborne
  • Martin D. Abeloff
  • Gabriel N. Hortobagyi
  • Daniel F. Hayes
  • Christine B. Ambrosone
Epidemiology

DOI: 10.1007/s10549-010-0840-0

Cite this article as:
Yao, S., Barlow, W.E., Albain, K.S. et al. Breast Cancer Res Treat (2010) 124: 433. doi:10.1007/s10549-010-0840-0

Abstract

To date, the few studies of associations between a functional polymorphism in the oxidative stress-related gene manganese superoxide dismutase (SOD2) and breast cancer survival have been inconsistent. In a homogeneous patient population from a large cooperative group trial Southwest Oncology Group (SWOG) 8897, we evaluated this polymorphism in relation to both treatment-related toxicity and disease-free survival (DFS). Among 458 women who received cyclophosphamide-containing adjuvant chemotherapy, those with variant C alleles, related to higher antioxidant activity, experienced less grade 3–4 neutropenia (OR = 0.52, 95% CI = 0.29–0.92) but had worse DFS (HR = 1.59, 95% CI = 0.99–2.55) than women with TT genotypes. No associations were observed among 874 women who were followed without adjuvant therapy. Our results are consistent with the hypothesis that women with higher SOD2 antioxidant activity may experience less treatment-related toxicity but shorter time to disease recurrence or death after breast cancer adjuvant chemotherapy, supporting the modifying effects of oxidative stress-related enzymes on cancer treatment toxicity and efficacy.

Keywords

SOD2 Polymorphism SNP Toxicity Disease-free survival 

Copyright information

© Springer Science+Business Media, LLC. 2010

Authors and Affiliations

  • Song Yao
    • 1
  • William E. Barlow
    • 2
  • Kathy S. Albain
    • 3
  • Ji-Yeob Choi
    • 4
  • Hua Zhao
    • 1
  • Robert B. Livingston
    • 5
  • Warren Davis
    • 1
  • James M. Rae
    • 6
  • I-Tien Yeh
    • 7
  • Laura F. Hutchins
    • 8
  • Peter M. Ravdin
    • 7
  • Silvana Martino
    • 9
  • Alan P. Lyss
    • 10
  • C. Kent Osborne
    • 11
  • Martin D. Abeloff
    • 12
  • Gabriel N. Hortobagyi
    • 13
  • Daniel F. Hayes
    • 6
  • Christine B. Ambrosone
    • 1
  1. 1.Department of Cancer and Prevention and Control, Roswell Park Cancer InstituteBuffaloUSA
  2. 2.Southwest Oncology Group Statistical CenterSeattleUSA
  3. 3.Loyola University Stritch School of MedicineMaywoodUSA
  4. 4.PharmacoGenomics Research CenterInje University College of MedicineBusanKorea
  5. 5.University of Arizona Cancer CenterTucsonUSA
  6. 6.University of Michigan Comprehensive Cancer CenterAnn ArborUSA
  7. 7.University of Texas Health Science Center at San AntonioSan AntonioUSA
  8. 8.University of Arkansas for Medical SciencesLittle RockUSA
  9. 9.The Angeles Clinic and Research InstituteSanta MonicaUSA
  10. 10.Heartland Cancer Research CCOPMissouri Baptist Medical CenterSt. LouisUSA
  11. 11.Baylor College of MedicineHoustonUSA
  12. 12.The Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsBaltimoreUSA
  13. 13.University of Texas M.D. Anderson Cancer CenterHoustonUSA

Personalised recommendations